Jazz Pharmaceuticals plc’s filing revealed that its Director Mulligan Seamus acquired Company’s shares for reported $9.83 million on May 09 ’25. In the deal valued at $98.26 per share,100,000 shares were bought. As a result of this transaction, Mulligan Seamus now holds 100,000 shares worth roughly $10.29 million.
Then, Mulligan Seamus bought 1,621 shares, generating $166,962 in total proceeds. Upon buying the shares at $103.00, the Director now owns 101,621 shares.
Before that, COZADD BRUCE C sold 1,000 shares. Jazz Pharmaceuticals plc shares valued at $116,350 were divested by the Chairman & CEO at a price of $116.35 per share. As a result of the transaction, COZADD BRUCE C now holds 439,307 shares, worth roughly $45.21 million.
UBS upgraded its Jazz Pharmaceuticals plc [JAZZ] rating to a Buy from a a Neutral in a research note published on March 07, 2025; the price target was increased to $179 from $145. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in late February from “an Overweight” to “a Neutral”. Wells Fargo also remained covering JAZZ and has increased its forecast on February 13, 2025 with a “an Overweight” recommendation from previously “an Equal weight” rating. Morgan Stanley revised its rating on December 12, 2024. It rated JAZZ as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of JAZZ
On Tuesday, Jazz Pharmaceuticals plc [NASDAQ:JAZZ] saw its stock fall -0.65% to $102.91. Over the last five days, the stock has lost -7.43%. Jazz Pharmaceuticals plc shares have fallen nearly -16.44% since the year began. Nevertheless, the stocks have fallen -9.03% over the past one year. While a 52-week high of $148.06 was reached on 02/26/25, a 52-week low of $95.49 was recorded on 04/09/25. SMA at 50 days reached $119.56, while 200 days put it at $118.69.
Levels Of Support And Resistance For JAZZ Stock
The 24-hour chart illustrates a support level at 101.66, which if violated will result in even more drops to 100.40. On the upside, there is a resistance level at 104.01. A further resistance level may holdings at 105.10. The Relative Strength Index (RSI) on the 14-day chart is 40.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -8.34, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.65%. Stochastics %K at 16.93% indicates the stock is a buying.
The most recent change occurred on June 05, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $169 price target.
